86549-28-2

Usage

Uses

Used in Organic Synthesis:
4-((Trimethylsilyl)ethynyl)isoquinoline is used as a building block in organic synthesis for the preparation of complex molecules. Its unique properties and reactivity make it a valuable component in the synthesis of various organic compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-((Trimethylsilyl)ethynyl)isoquinoline is used as a key intermediate for the development of pharmaceuticals and other biologically active compounds. Its presence in these compounds can contribute to their therapeutic effects and potential applications in medicine.
Used in Chemical Research and Drug Discovery:
4-((Trimethylsilyl)ethynyl)isoquinoline is also utilized in chemical research and drug discovery as a valuable tool. Its unique structure and reactivity allow researchers to explore new chemical reactions and pathways, potentially leading to the discovery of novel compounds with therapeutic potential.

Upstream product

• 1532-97-4 4-bromoisoquinoline 
• 1066-54-2 trimethylsilylacetylene 
• 7681-65-4 copper(I) iodide 
• 55270-33-2 4-iodo-isoquinoline 

Relevant academic research and scientific papers

Synthesis and in vitro biological evaluation of (iso)quinoline-1,2,3-triazole derivatives as anticancer agents

Two series of triazole derivatives were designed and synthesized as potential anticancer agents. A series of eighteen novel 1,2,3-triazole derivatives were synthesized through copper catalyzed click reaction. The compounds were evaluated for their cytotoxicity activity against HepG2, HeLa cell and HEK293 cell lines using MTT assay. The results showed that compounds 10 and 11 were the most potent compounds against HepG2 cell with IC50 values 9.6 and 13.3?μM, respectively. Additionally, the compounds 10 and 11 were the most potent compounds against HeLa cell with IC50 values 5.7 and 5.8?μM, respectively. The results of tubulin polymerization assay demonstrated that lead compound 2 and compound 10 could inhibit in vitro tubulin polymerization. In addition, a mechanism study displayed that 10 blocked cell cycle arrest at G2/M phase. Furthermore, a molecular docking study demonstrated that 10 can bind to the colchicine site of tubulin and form hydrogen bonds in the active site of β-tubulin. In summary, our study recommends a promising isoquinoline-triazole scaffold for further development as more efficient microtubule polymerization inhibitors in the field of cancer treatment. Graphical abstract: [Figure not available: see fulltext.]

Novel Class of Colony-Stimulating Factor 1 Receptor Kinase Inhibitors Based on an o-Aminopyridyl Alkynyl Scaffold as Potential Treatment for Inflammatory Disorders

Colony-stimulating factor 1 receptor (CSF-1R) is involved in inflammatory disorders as well as in many types of cancer. Based on high-throughput screening and docking results, we performed a detailed structure-activity-relationship study, leading to the d

Aryl Nitriles from Alkynes Using tert -Butyl Nitrite: Metal-Free Approach to C≡C Bond Cleavage

Alkyne C≡C bond breaking, outside of alkyne metathesis, remains an underdeveloped area in reaction discovery. Recently, nitrogenation has been reported to allow nitrile formation from alkynes. A new protocol for the metal-free C≡C bond cleavage of terminal alkynes to produce nitriles is reported. This method provides an opportunity to synthesize a vast range of nitriles containing aryl, heteroaryl, and natural product derivatives (38 examples). In addition, the potential of tBuONO to act as a powerful nitrogenating agent for terminal aryl alkynes is demonstrated. (Figure Presented).

Aerobic oxynitration of alkynes with tBuONO and TEMPO

An efficient method for stereoselective nitroaminoxylation of alkyne has been reported. The reaction enjoys a broad substrate scope, good functional group tolerance, and high yields. Synthetically useful α-nitroketones can be accessed through these products in a single step.

CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE COMPRISING THE SAME

Embodiments of the present invention are directed to a condensed-cyclic compound represented by Formula 1, and to an organic light-emitting diode including the same.

Condensed-cyclic compound and organic light-emitting diode comprising the same

Embodiments of the present invention are directed to a condensed-cyclic compound represented by Formula 1, and to an organic light-emitting diode including the same.

Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.